Dr Arnon Kater speaks to ecancer about the new 5-yr analysis of the MURANO trial, looking at sustained disease survival in previously treated chronic lymphocytic leukaemia (CLL) patients after three years of venetoclax rituximab treatment, pointing to fixed duration treatment with this combination. This study was presented at this year’s ASH conference.
Dr Kater first talks about what the MURANO trial was about and then moves on to explain what this 5-year analysis investigated. He says that this five-year, follow-up analysis from the Phase 3 MURANO trial shows median progression-free survival (PFS) of 53.6 months in previously treated CLL patients taking venetoclax in combination with rituximab compared to 17.0 months in patients taking bendamustine plus rituximab (BR) after three years or more off treatment.
He further states that two analyses of the Phase 3 CLL14 study evaluated minimal residual disease (MRD) measurements for previously untreated CLL patients taking venetoclax in combination with obinutuzumab. Dr Kater in the end talks about the key results and what impact can these results have in the future treatment of CLL patients.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.